Evalution of the effect of obesity-associated inflammation on the response to complex therapy in hypertensive elderly patients with coronary artery disease
Keywordspharmacotherapy, efficacy, hypertension, obesity, inflammation
Object: to identify factors that limit the effectiveness of pharmacotherapy of hypertension (HT) with comorbid coronary artery disease (CAD) in elderly obese patients by determining laboratory and spectroscopy features related to inflammation.
Material and methods: 60 patients (68.2 ± 5.9 y.o.) were observed and treated in Internal Medicine Department of University Clinic of Odessa National Medical University. Patients were divided into 2 groups. The 1st group included patients (n = 30) with body mass index (BMI) ≤25 kg/m2, HT and co-morbid CAD; the 2nd group (n = 30) - patients with BMI≥30 kg/m2, HT and with co-morbid CAD. For each patient’s group antihypertensive combination of Lisinopril and Bisoprolol was prescribed. The Laser correlation spectroscopy (LCS) was a special method for investigation.
Results: before pharmacotherapy (PT) in both groups according to LCS 11-150 nm particles are prevailing. But in obese patients 75th percentile of 31-70 nm particles exceeds that one in non-obese group (56.7% vs 30.5%). During PT systolic blood pressure (SBP) value normalized in the patients of 1st group (without obesity), while in the obese patients (2nd group) SBP remained above target level. Creatinine level increased in patients of 1st group (without obesity) by 16.5 μmol / L (p <0.05) with a decrease in GFR by 17.1 ml/min/1.73 m2 (P <0.05). LCS data during PT show increase of 11-30 nm and decrease of 75-150 nm particles in non-obese patients, while in obese patients 71-150 nm particles are prevailing and 150 nm particles have appeared (p<0.05).
Conclusions: 1. In elderly hypertensive patients with concomitant CAD, obesity is a factor limiting the effectiveness of complex antihypertensive therapy. 2. An increase of proportion of allergic-directed and appearance of autoimmune-directed homeostatic shifts in serum according to LCS are associated with a decrease of antihypertensive therapy efficacy in elderly hypertensive patients with CAD and obesity. 3. In hypertensive non-obese patients with CAD under the influence of complex antihypertensive therapy deteriorating of renal function is observed while in obesity renal function is not changed. 4. Homeostatic changes revealed in the second group by LCS values probably reflect manifestation of low grade inflammatory process caused by excessive activity of adipose tissue.
Shtanko V.A., Tofan N.V. Peculiarities of comorbidity structure and combined pharmacotherapy in ischemic heart disease combined with primary arterial hypertension in elder age. Achievements of biology and medicine, 2013. Vol. 21(1). P. 47–51.
Tofan N.V. Systematization of comorbid pathology and pharmacotherapy features in cardiological patients of elder age. Aptitude, 2013. Vol. 15. P. 172.
Philip A. Ades, Patrick D. Savage. Obesity in Coronary Heart Disease: An Unaddressed Behavioral Risk Factor. Preventive Medicine, 2017. Vol. 4. P. 117-119.
Kovalenko V.M, Kornatsky V.M. Health and medical aid problems and the model of improvement in modern conditions. Manual released by National scientific center “Institute of cardiology named by Strajesko M.D.”, 2017. 300 p.
Verdecchia P., Angeli F., Cavallini C. et al. Sudden Cardiac Death in Hypertension Patients. Hypertension, 2019. Vol. 73. P. 1071-1078.
Tofan N.V. Correction of hemodynamic parameters in elderly patients with primary arterial hypertension combined with ischemic heart disease depending of left ventricular hypertrophy, obesity and multiple comorbidity presence. Achievements of biology and medicine, 2015. Vol. 25(1). P. 59–63.
Maugeri A., Hruskova J., Jakubik J. et al. Independent effects of hypertension and obesity on left ventricle mass and geometry: evidence from the Cardiovision 2030 Study. Journal of Clinical Medicine, 2019. Vol. 8(3). P. 370.
Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest., 2006. Vol. 116, № 6. P.1494-1505.
Miller M.A., Cappuccio F.P. Cellular adhesion molecules and their relationship with measures of obesity and metabolic syndrome in a multiethnic population. Int J Obes, 2006. Vol. 30, № 8. P.1176-1182.
Constant V.A., Gagnon A., Yarmo M., Sorisky A. The antiadipogenic effect of macrophage-conditioned medium depends on ERK1/2 activation. Metabolism, 2008. Vol. 57 (4). P. 465- 472.
Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis, 2003. Vol. 170, № 2. P.191-203.
Ruan H., Miles P.D., Ladd C.M., Ross K., Golub T.R., et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes, 2002. Vol. 51(11). P. 3176-3188.
Zhu J., Yong W., Wu X., Yu Y., Lv J., et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun., 2008. Vol. 369(2). P. 471- 477.
Abaturov A.E. Peculiarities of metabolic syndrome in children. Pediatrician, 2001. № 4. P.54-61.
Nishimura S., Manabe I., Nagasaki M., Seo K., Yamashita H., et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest., 2008. Vol.118, № 2. P.710-21.
Kampf C., Bodin B., Källskog Ö., Carlsson C., Jansson L. Marked Increase in White Adipose Tissue Blood Perfusion in the Type 2 Diabetic GK Rat. Diabetes, 2005. Vol.54, № 9. P.2620.
Simonsen L., Enevoldsen LH., Bülow J. Determination of adipose tissue blood flow with local 133Xe clearance. Evaluation of a new labelling technique. Clin Physiol Funct Imaging, 2003. Vol.23, № 6. P.320-323.
Trayhurn P., Wang B.,Wood I.S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr., 2008. Vol.100, № 2. P. 227-235.
2018 ESC Guidelines. European Heart Journal, Vol. 39, Issue 33. P. 3021–3104.
Bazhora Y.I., Noskin L.O. Laser correlation spectroscopy in medicine: monograph. Odessa: “Druk”, 2002. 400 pages.
Zaporozhan V.M., Noskin L.O., Kresyun V.I. Factors and mechanisms of sanogenesis: monograph. Odessa: ONMedU, 2014. P. 217-334.
Gronevold J., Cropp R., Lehmann N. et al. Cardio-vascular risk and atherosclerosis progression in hypertensive persons treated to blood pressure targets. Hypertension, 2019. Vol. 74. P. 1436-1447.
Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of all cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA, 2013. Vol. 309 (1). P. 71-82.
Angeras O., Albertsson P., Karason K., et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J, 2013. Vol. 34 (5). P. 345-353.
Savage M.P., Fischman D.L.. Percutaneous coronary intervention and the obesity paradox: fat chance. JACC Interv, 2018. Vol. 11. P. 77-79.
Faggioni M., Baber U., Afshar A.E., et al. Effects of body mass index on clinical outcomes in female patients undergoing percutaneous coronary intervention with drug-eluting stents: results from a patient-level pooled analysis of randomized clinical trials. JACC Cardiovasc Interv., 2018. Vol. 11 (1). P. 68-76.
Aronson D., Nassar M., Goldberg T., et al. The impact of body mass index on clinical outcomes after acute myocardial infarction. Int J Cardiol., 2010. Vol. 145 (3). P. 476-480.
Chumakova G.A., Pokutnev A.P., Veselovskaya N.G. Clinical specifics of patients state after revascularized myocardial infarction, depending on the baseline obesity status. Russ J Cardiol, 2018. Vol. 23 (5). P. 21–26.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 164
Number of citations: 0